Recent Finacing
Recent Raise
Neumedicines develops recombinant human IL‑12 therapies; lead candidate HemaMax targets hematopoietic acute radiation syndrome and hematological adjuvant cancer therapy, advancing from animal efficacy to human safety toward FDA BLA.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor